Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1842582 | 0.84 | PKM (0.45) | L3MBTL1ALDH1A1TDP1PKMLMNA | |
| SCHEMBL1942265 | 0.81 | ALDH1A1 (0.35) | L3MBTL1ALDH1A1TDP1LMNATSHR | |
| SCHEMBL4033098 | 0.77 | ALDH1A1 (0.33) | L3MBTL1ALDH1A1TDP1PKMLMNA | |
| SCHEMBL4032511 | 0.71 | SMN1; SMN2 (0.37) | L3MBTL1ALDH1A1LMNATSHRMAPT | |
| SCHEMBL5849034 | 0.71 | MAPT (0.42) | L3MBTL1ALDH1A1TDP1PKMLMNA | |
| SCHEMBL5849016 | 0.71 | HSD11B1 (0.45) | L3MBTL1ALDH1A1LMNATSHRMAPT | |
| SCHEMBL13791534 | 0.68 | PKM (0.52) | L3MBTL1ALDH1A1TDP1PKMLMNA | |
| SCHEMBL1845472 | 0.67 | TDP1 (0.40) | L3MBTL1ALDH1A1TDP1PKMLMNA | |
| SCHEMBL1840183 | 0.67 | ALDH1A1 (0.40) | L3MBTL1ALDH1A1TDP1PKMLMNA | |
| SCHEMBL1840299 | 0.66 | TDP1 (0.39) | L3MBTL1ALDH1A1TDP1PKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1555265-B1 | 7-PHENYL PYRAZOLOPYRIDINE COMPOUNDS | EISAI R&D MAN CO LTD (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-20080076943-A1 | 7-PHENYLPYRAZOLOPYRIDINE COMPOUNDS | HIBI SHIGEKI | 2008-03-27 | — | — | US | disclosed |
| US-20080076943-A1 | 7-PHENYLPYRAZOLOPYRIDINE COMPOUNDS | HIBI SHIGEKI | 2008-03-27 | — | — | US | disclosed |
| US-20080076943-A1 | 7-PHENYLPYRAZOLOPYRIDINE COMPOUNDS | HIBI SHIGEKI | 2008-03-27 | — | — | US | disclosed |
| US-7323569-B2 | 7-phenylpyrazolopyridine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-29 | — | — | US | disclosed |
| US-7323569-B2 | 7-phenylpyrazolopyridine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-29 | — | — | US | disclosed |
| US-7323569-B2 | 7-phenylpyrazolopyridine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-29 | — | — | US | disclosed |
| US-7176216-B2 | 7-phenylpyrazolopyridine compounds | EISAI CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176216-B2 | 7-phenylpyrazolopyridine compounds | EISAI CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176216-B2 | 7-phenylpyrazolopyridine compounds | EISAI CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20060235011-A1 | 7-Phenyl pyrazolopyridine compounds | EISAI CO.LTD. (JP) | 2006-10-19 | — | — | US | disclosed |
| EP-1555265-A1 | 7-PHENYL PYRAZOLOPYRIDINE COMPOUNDS | Eisai Co., Ltd. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20040224974-A1 | 7-phenylpyrazolopyridine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224974-A1 | 7-phenylpyrazolopyridine compounds | CRHR1, MC2R, CRH | L3MBTL1 3124/4885ALDH1A1 2616/4885TDP1 2246/4885 |
| US-20080076943-A1 | 7-PHENYLPYRAZOLOPYRIDINE COMPOUNDS | MC2R, CRHR1, CRHR2 | L3MBTL1 3153/4885ALDH1A1 3348/4885TDP1 2552/4885 |
| US-20060235011-A1 | 7-Phenyl pyrazolopyridine compounds | MC2R, CRHR1, CRHR2 | L3MBTL1 3260/4885ALDH1A1 3334/4885TDP1 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.